Hengrui's Shudi Insulin Injection Approved as China's First Homegrown Long-Acting Insulin Analogue
Hengrui Medicine's independently developed Class 1 therapeutic biologic Shudi Insulin Injection has received approval from the National Medical Products Administration (NMPA) for market launch. The product is China's first domestically developed long-acting insulin analogue. Hengrui Medicine announced this news on July 29.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 75/100 and 85% confidence over a medium term horizon.
Healthcare · 13.1
Pharmaceuticals
- Direction
- positive
- Intensity
- 75
- Confidence
- 85%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 70
- Confidence
- 80%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.